http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2690674-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b2638f6c090160b33fa8fbcf849f94c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-557 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-65 |
| filingDate | 2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_929a4a8266e258e8a15cf8ad6c3c3dbd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e98426676a3908139e859df9010e7f9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fad28294a59129b23451e454fcd1dbbb |
| publicationDate | 2019-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2690674-C2 |
| titleOfInvention | 2-ethyl-6-methyl-3-hydroxypyridine orotate dihydrate and method for production thereof |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to novel 2-ethyl-6-methyl-3-hydroxypyridine orotate dihydrate salt and a method for production thereof. 2-Ethyl-6-methyl-3-hydroxypyridine orotate dihydrate corresponds to formula C 8 H 11 NO⋅C 5 H 4 N 2 O 4 ⋅2H 2 O. 2-Ethyl-6-methyl-3-hydroxypyridine orotate dihydrate can be used to produce a pharmaceutical composition for preventing and/or treating hypoxia, including 2-ethyl-6-methyl-3-hydroxypyridine orotate and a pharmaceutically acceptable carrier. Method of producing orotate involves A) 2-ethyl-6-methyl-3-hydroxypyridine (1000.0 mg) is dissolved in isopropyl alcohol (5 ml) at room temperature; B) orotic acid 56.9 mg (0.000364479 mol) is dissolved in 5 ml of a mixture of acetonitrile / water (1:1) at temperature of 80 °C; B) and adding 250 mcl of solution of 2-ethyl-6-methyl-3-hydroxypyridine (0.000364479 mole) obtained above; D) obtained mixture is cooled to room temperature naturally, precipitate is released 20–30 minutes after preparation. Product is obtained in form of a monocrystal. According to thermogravimetry and X-ray structural analysis, 2-ethyl-6-methyl-3-hydroxypyridine monochloride orotate dihydrate has an endothermic peak of 90–115 °C according to differential scanning calorimetry and peaks measurement data 2Θ° 8.1, 9.1, 10.0, 12.5, 12.9, 13.9, 15.2, 15.5, 18.0, 19.4, 19.6, 21.6, 22.1, 25.5, 28.7, 29.8, 30.4, 32.3 on X-ray diffraction measurements. n EFFECT: compound can be used as a antihypoxic agent for preventing or treating cardiovascular diseases, including atherosclerosis, myocardial dystrophy, anemia, IHD, including angina pectoris, myocardial infarction, chronic cardiac failure and heart rhythm disturbances, including magnesium-dependent arrhythmia, atrial fibrillation, or as an adjunct to liver diseases, including hepatitis, hepatosis and bile ducts caused by acute and chronic intoxication, except for organic damages of liver and bile ducts. n 8 cl, 6 dwg, 1 ex |
| priorityDate | 2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.